Acoustic Blood Pressure Measurement On Implanted Biomedical Surfaces
Funder
National Health and Medical Research Council
Funding Amount
$184,687.00
Summary
Measurement of local blood pressure in is of great clinical importance. An application of particular interest is the pressure measurement in and around endoluminal stents grafts, which are used for the treatment of Abdominal Aortic Aneurysms (AAAs). These grafts are implanted by keyhole surgery and are used to reduce the pressure on the aneurysm walls so that the artery can revert to its more anatomically correct shape on a timescale of one to two years. If the seal between the graft and the art ....Measurement of local blood pressure in is of great clinical importance. An application of particular interest is the pressure measurement in and around endoluminal stents grafts, which are used for the treatment of Abdominal Aortic Aneurysms (AAAs). These grafts are implanted by keyhole surgery and are used to reduce the pressure on the aneurysm walls so that the artery can revert to its more anatomically correct shape on a timescale of one to two years. If the seal between the graft and the artery wall is not blood tight, then the aneurysm can become repressurised and may keep on expanding. Over time, an untreated, expanding AAA is likely to rupture with severe consequences for the patient. Thus a convenient, non-invasive means of measuring the pressure within the aneurysm and within the graft is highly desirable. In this proposal, we seek to produce a device that can be incorporated into the walls of the endoluminal graft, which can measure absolute pressure inside and outside the graft and where the pressure measurements can be obtained via standard acoustic or medical ultrasound equipment. To do this, we would use specially designed 'bubbles' which can be incorporated onto either side of the graft walls, where the resonant frequency of the bubbles provides a direct measurement of the pressure around the bubbles. Trials at the CSIRO have found that pressures can be measured to a resolution of better than 10 mmHg by using this technique on air bubbles in water. In this proposal, we wish to develop flexible, but semi-permanent bubbles that can be incorporated onto a biomedical implant surface. If such bubbles can be made, the researchers will use CSIRO-developed software and acoustic equipment such that local blood pressure can be measured in real time.Read moreRead less
Prototype Medical Device For The Automatic Detection And Suppression Of Epileptic Seizures And Ex Vivo Studies In Humans
Funder
National Health and Medical Research Council
Funding Amount
$419,239.00
Summary
This project aims to extend on work that The Bionic Ear Institute has been conducting into the termination of seizures using electrical stimulation of the brain. A device will be constructed that is capable of monitoring the electrical activity of the brain via electrodes. If abnormal activity is detected, a therapeutic waveform will be delivered in order to terminate the epileptic event. Such a device would offer new therapeutic options to many sufferers of epilepsy worldwide.
Development Of A Humanised Antibody For Treatment Of Cancer And Stroke
Funder
National Health and Medical Research Council
Funding Amount
$400,142.00
Summary
The protein PDGF-CC has a critical role in blood vessel development, and is implicated in the development of cancer, and the debilitating consequences of acute stroke. Researchers in the Ludwig Institute for Cancer Research have developed novel anti-PDGF-CC antibodies. The research program proposed will generate data and clinical reagents that will enable a lead candidate anti-PDGF-CC antibody to be commercialised, and ultimately evaluated clinically in cancer and stroke patients.
Production Of A Novel Humanised Anti Dendritic Cell Therapeutic Antibody For Graft Versus Host Disease
Funder
National Health and Medical Research Council
Funding Amount
$202,500.00
Summary
A transplant of bone marrow or other source of blood stem cells from a donor is often used to treat leukaemia patients whose disease has failed to respond to chemotherapy. The Mater Medical Research Institute has developed a world first dendritic cell depleting therapeutic antibody which may open a new strategy for the control of acute graft versus host disease, which is a very common and often fatal complication of bone marrow transplantation. The new antibody treatment is also likely to be use ....A transplant of bone marrow or other source of blood stem cells from a donor is often used to treat leukaemia patients whose disease has failed to respond to chemotherapy. The Mater Medical Research Institute has developed a world first dendritic cell depleting therapeutic antibody which may open a new strategy for the control of acute graft versus host disease, which is a very common and often fatal complication of bone marrow transplantation. The new antibody treatment is also likely to be useful for the prevention of rejection in solid organ transplantation. If successful, it will selectively control graft versus host disease, without compromising the essential anti-viral immunity and desired anti-leukemia activity of the graft.Read moreRead less
Chronic infections and cancers are major causes of global disease burden. Harnessing the immune system to combat these diseases has proven difficult and cumbersome to date. We invented a new technology to boost the ability of the immune system to fight chronic infections such as AIDS and Hepatitis C. This involves using someone�s own blood treated with sets of short proteins. We term this therapy Overlapping Peptide Pulsed Autologous CelLs (OPAL). This shows great promise in robust animal models ....Chronic infections and cancers are major causes of global disease burden. Harnessing the immune system to combat these diseases has proven difficult and cumbersome to date. We invented a new technology to boost the ability of the immune system to fight chronic infections such as AIDS and Hepatitis C. This involves using someone�s own blood treated with sets of short proteins. We term this therapy Overlapping Peptide Pulsed Autologous CelLs (OPAL). This shows great promise in robust animal models. We now propose to refine this technique in animals in preparation for human clinical trials.Read moreRead less
The DietAdvice Website A New Innovation For Dietitians In Clinical Practice.
Funder
National Health and Medical Research Council
Funding Amount
$140,975.00
Summary
Due to the growing incidence of obesity within Australia, use of computer technology may be a method of targeting these people by increasing access to dietary services. Currently available dietary software in the Australian context only allows analysis of nutrient information. Thus when a dietitian sees a patient they must manually translate food intake to nutrient information, a largely time consuming exercise. DietAdvice is a website that was developed for people to enter in their own food int ....Due to the growing incidence of obesity within Australia, use of computer technology may be a method of targeting these people by increasing access to dietary services. Currently available dietary software in the Australian context only allows analysis of nutrient information. Thus when a dietitian sees a patient they must manually translate food intake to nutrient information, a largely time consuming exercise. DietAdvice is a website that was developed for people to enter in their own food intakes. The food information is sent to a dietitian who develops individualised dietary advice for them. A pilot study of the website has already found it to be feasible in the primary healthcare setting. Tested for 12 months the website was used by 224 patients from GP practices in the Illawarra region of NSW. Approximately 73% of patients were overweight and patients with a high BMI were 1.88 times more likely to use the website in the comfort of their home. Further research about the website however was needed. The research to follow on from the pilot study will aim to refine the DietAdvice website, leading towards its commercialisation for dietitians in clinical practice. The research will be broken into 3 phases. Phase 1 will involve a usability test of the website, assessing the underlying algorithms and testing it with dietitians in private practice. Phase 2 will see volunteers using the website on multiple occasions after being given pre-weighed amounts of food to eat. This will determine how reliable and accurate the information is; and phase 3 will evaluate whether the website is cost effective and if it increases accessibility of health services especially in rural areas. By confirming these attributes there will be a sound basis to commercialise the product.Read moreRead less
Application Of Follistatin To The Resolution Of Liver Fibrosis
Funder
National Health and Medical Research Council
Funding Amount
$330,990.00
Summary
Liver fibrosis or scarring is a consequence of a number of diseases, leading eventually to extensive damage known as cirrhosis. It is a significant health problem both here in Australia and overseas with around 180,000 patients diagnosed each year in the Western world. Cirrhosis arises from many causes, two major groups being patients who contract hepatitis and alcoholics. People with cirrhosis have a much increased risk of liver failure, which requires liver transplantation, or of developing li ....Liver fibrosis or scarring is a consequence of a number of diseases, leading eventually to extensive damage known as cirrhosis. It is a significant health problem both here in Australia and overseas with around 180,000 patients diagnosed each year in the Western world. Cirrhosis arises from many causes, two major groups being patients who contract hepatitis and alcoholics. People with cirrhosis have a much increased risk of liver failure, which requires liver transplantation, or of developing liver cancer, for which current treatments have limited success. We have been studying two proteins, activin and follistatin, both of which are made in the liver. We are interested in activin because it is one of the body's mechanisms to control cell growth, and also seems to stimulate the development of scar tissue. Follistatin is the natural inhibitory substance for activin. It blocks the effects of activin and helps promote cell growth in the liver. We believe that follistatin may also be useful in controlling liver scarring. This process will be studied in animal models of cirrhosis, in the hope that follistatin treatment will reduce the level of liver damage. If successful, this would be important information that would enable us to design treatments applicable to human sufferers of these liver diseases. In another part of the project, we will assess whether activin and follistatin might be useful markers of liver disease. Most patients require a liver biopsy to assess the amount of liver damage, and a simple blood test would be a far easier, less traumatic and cheaper alternative.Read moreRead less
The Development Of Novel, Biofilm-resistant Biomaterials
Funder
National Health and Medical Research Council
Funding Amount
$147,360.00
Summary
Almost all patients who are catheterised long term develop a bacterial infection. Most often, the infection is the result of colonisation of the catheter surface by bacteria. Bacterial colonisation of the surface of biomedical devices represents a significant health threat as such bacterial biofilms are extremely resistant to traditional antibiotic regimens. This project aims to develop novel materials that prevent bacterial colonisation on catheters and other biomedical related devices. Our tec ....Almost all patients who are catheterised long term develop a bacterial infection. Most often, the infection is the result of colonisation of the catheter surface by bacteria. Bacterial colonisation of the surface of biomedical devices represents a significant health threat as such bacterial biofilms are extremely resistant to traditional antibiotic regimens. This project aims to develop novel materials that prevent bacterial colonisation on catheters and other biomedical related devices. Our technology is based on compounds identified from a marine alga that prevent bacterial colonisation of its surface. Similarly, we have shown that these compounds, when coated onto test surfaces, prevent bacterial colonisation of a range of materials.Read moreRead less
Development Of A Serum Based Test For Aggressive Prostate Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$144,950.00
Summary
Prostate cancer is relatively slow growing, taking decades to reach clinical significance. A critical phase in the progression of prostate cancer is the transformation from latent (or dormant) to aggressive tumours; hence the saying that many men die with prostate cancer, rather than of prostate cancer. We aim to develop a test utilising inhibin-activin proteins as surrogate markers of aggressive disease based on our previous studies of a significant correlation between the expression of inhibin ....Prostate cancer is relatively slow growing, taking decades to reach clinical significance. A critical phase in the progression of prostate cancer is the transformation from latent (or dormant) to aggressive tumours; hence the saying that many men die with prostate cancer, rather than of prostate cancer. We aim to develop a test utilising inhibin-activin proteins as surrogate markers of aggressive disease based on our previous studies of a significant correlation between the expression of inhibins in tissues from men with high grade prostate cancer. This study aims to validate the correlation using serum rather than a tissue based assay.Read moreRead less